Purple AI announced on the 19th that it had attracted 2.5 billion won in pre-A investment. Murex Partners, Big Basin Capital, Mashup Ventures, and Digital Healthcare Partners (DHP) participated in this investment round. Based on this, Purple AI will expand its solution lineup and pursue full-scale entry into the global market.
Purple AI is a startup jointly founded by SK C&C's AI Healthcare team and professors of radiology from Seoul National University Hospital and Ajou University Hospital. It has been conducting joint research and development (R&D) with three institutions since 2019. Through this, it has developed medical device solutions such as cerebral hemorrhage AI, cerebral infarction AI, and cerebral aneurysm AI, obtained approval, and applied them to approximately 40 general hospitals nationwide to prove their clinical effectiveness.
The main product, 'Medical Insight Plus Cerebral Hemorrhage', is a service that analyzes brain CT images within seconds and informs medical staff of the location of the hemorrhage and any abnormalities with 98% accuracy. It has been proven in numerous clinical studies to be effective in shortening the golden time for cerebral hemorrhage patients, increasing diagnostic accuracy, and improving treatment efficiency in emergency rooms. This technology has been designated as an innovative medical technology by the Ministry of Health and Welfare, and has also obtained product approval from the US FDA.
“Purple AI’s solution has been verified for AI accuracy and processing speed in domestic medical settings, and has proven its global competitiveness through FDA clinical trials,” said Younghyun Ahn, senior analyst at Murex Partners, who led this round. “In particular, the field of brain disease diagnosis is a market where medical professionals have a high need for AI adoption and global insurance coverage is actively applied, which was an important factor in our investment decision.”
Purple AI plans to use this investment to accelerate the expansion of its AI solutions and its entry into the global market. In addition to the current image diagnosis AI, it is developing an AI model for predicting the prognosis of cerebral hemorrhage using patient metadata, and is preparing to expand indications for stroke-related brain diseases. It is also pursuing partnerships with PACS and cloud platform companies, focusing on the North American market.
Park Byung-jun, CEO of Purple AI, said, “This investment is a recognition of our AI technology and medical domain expertise, and we will focus on completing a comprehensive AI platform for brain diseases and achieving global success.”
You must be logged in to post a comment.